Nazem Ahmad A, Ruzevick Jacob, Ferreira Manuel J
Department of Neurosurgery, University of Washington School of Medicine, University of Washington Medical Center, Seattle, WA 98195, USA.
These authors contributed equally to this work.
Oncotarget. 2020 Dec 8;11(49):4544-4553. doi: 10.18632/oncotarget.27841.
Meningiomas are a heterogeneous group of tumors, defined histo-pathologically by World Health Organization (WHO) grading. The WHO grade of meningiomas does not always correlate with clinical aggressiveness. Despite maximal surgical resection and adjuvant radiation, a subset of tumors are clinically aggressive; displaying early recurrence and invasion. Current methods for identifying aggressive meningiomas solely focus on genomics, proteomics, or epigenetics and not a combination of all for developing a real-time clinical biomarker. Improved methods for the identification of these outlying tumors can facilitate better classification and potentially adjuvant treatment planning. Understanding the pathways of oncogenesis using multiple markers driving aggressive meningiomas can provide a foundation for targeted therapies, which currently do not exist.
脑膜瘤是一组异质性肿瘤，通过世界卫生组织（WHO）分级进行组织病理学定义。脑膜瘤的WHO分级并不总是与临床侵袭性相关。尽管进行了最大程度的手术切除和辅助放疗，但仍有一部分肿瘤具有临床侵袭性，表现为早期复发和侵袭。目前识别侵袭性脑膜瘤的方法仅侧重于基因组学、蛋白质组学或表观遗传学，而不是将所有这些结合起来以开发实时临床生物标志物。改进的识别这些异常肿瘤的方法可以促进更好的分类，并可能有助于辅助治疗计划。利用驱动侵袭性脑膜瘤的多种标志物来了解肿瘤发生途径可为目前不存在的靶向治疗提供基础。
